Hong Kong (HQ)ShanghaiZurichChicago
China Biotech

Your access point to China biotech.

Greater China is the most dynamic source of clinical-stage innovation in life sciences today. We help global pharma and biotech navigate it: market intelligence, asset sourcing, principal introductions, and end-to-end deal execution.

Resident China deskBilateral sourcing / no brokersMandarin-native China coverage
A meeting ending in a Shanghai office overlooking Lujiazui
China desk / pulse2026
$73B
Outbound deal value originating in Greater China, 2024 – H1 2026
VLS China desk analysis
Trial cost vs. US
~60%
Indicative on Phase 2 oncology pivotal
Enrollment speed vs. US
2 - 5x
Driven by site density and patient pool
Greater China outbound deals
120+
Calendar 2025, all modalities
VLS mandates in corridor
Hundreds
Since the firm began operating
A research lead explaining results to a visiting business development executive
How we help

Four ways to work the corridor with us.

Whether you are scoping a market thesis, sourcing a specific asset, or executing a deal: partner-led across every step.

/ 01

Market intelligence

Targeted briefs on indications, modalities, and counterparty universes. Quarterly China desk read on what's clearing term sheets and why.

/ 02

Asset sourcing

Bilateral search across Greater China innovators, academic spin-outs, and listed pharma. We triage candidates to your thesis, with written rationale.

/ 03

Principal introductions

Direct introductions to BD heads and decision-makers at validated counterparties. No brokers. No mass outreach.

/ 04

Deal execution

End-to-end from term sheet through definitive: diligence coordination, regulatory pathway, IP, CMC, and post-close integration.

Why now

Four shifts that turned a curiosity into a corridor.

The pace of outbound deal flow is not a cycle. It compounds four structural changes every global buyer should be operating with.

/ 01

Clinical infrastructure has matured.

NMPA pivotal data is increasingly accepted by FDA and EMA in MRCT designs, narrowing the trial-quality gap and shortening parallel filings.

/ 02

Capital has reset on the seller side.

Domestic financing dynamics have shifted incentives toward earlier, cleaner partnership conversations and away from holding for IPO at any cost.

/ 03

Modality leadership has emerged.

ADCs, bispecifics, GLP-1 combinations, and cell therapy are no longer follow-on. Chinese assets now lead several sub-categories outright.

/ 04

Buy-side BD has caught up.

Global pharma is dedicating standing capacity to inbound sourcing from Greater China. What was opportunistic in 2022 is structural in 2026.

What is hot

Where deal flow is most concentrated right now.

A read on which modalities are clearing the most term sheets, what stage of the curve they are at, and how that shapes diligence.

Modality
What is distinctive
Stage
Activity
ADC
Topoisomerase and novel-payload chemistry leading in-class on multiple solid tumor targets.
Phase 2 / 3 - Late-stage tail forming
Very hot
Bispecific
T-cell engagers across CD3-paired tumor antigens; subcutaneous administration emerging.
Phase 2 - Expansion
Very hot
GLP-1 / Metabolic
Dual and triple incretin agonists; oral bioavailability programs maturing.
Phase 2 readouts - Active
Very hot
Cell & gene
CAR-T and allogeneic platforms; engineered safety switches differentiated.
Phase 2 - Maturing
Hot
Immunology
JAK1-selective and S1P-modulator small molecules with cleaner safety than first-generation in-class.
Phase 2 / 3 - Selective
Hot
CNS / Rare
Targeted small-molecule and gene-therapy programs; deal flow more concentrated, fewer credible assets.
Phase 1 / 2 - Emerging
Steady
House view
The China outbound conversation is not about price any more. It is about who you trust to source for you.
From the partnersVision Lifesciences / China Desk
Diligence framework

What changes when an asset comes from Greater China.

Standard diligence frameworks miss six questions that decide outcomes on cross-border Chinese mandates. We have run each of them, on the buy and sell side. For the two rules that changed in October 2026, see our guide to the COINS Act and China’s new biotech export rules.

/ 01

Trial population translatability

Standard-of-care benchmarks in a Chinese pivotal may not map to your primary commercial geographies. Diligence reads the trial through the buyer's reimbursement lens.

/ 02

CMC & ex-China supply

Manufacturing readiness for ex-China supply is now deal-determining. Capacity, comparability, and supply-chain redundancy surface value or risk at term-sheet stage.

/ 03

IP freedom in target geographies

Patent estates may have material gaps outside the home jurisdiction. A current FTO opinion in target territories is now a baseline deliverable.

/ 04

NMPA to FDA regulatory path

MRCT design, breakthrough designations, and parallel filings can compress timelines significantly when set up correctly and add years when not.

/ 05

BIOSECURE, COINS & export-control exposure

We assess counterparty exposure under BIOSECURE, the US outbound investment (COINS Act) rules, China’s technology export controls, EAR, and adjacent regimes at intake. Documented written conclusions before signature.

/ 06

Counterparty operational maturity

Domestic Chinese counterparties vary widely in BD discipline and post-signing execution. We map the operating reality, not the deck.

Selected reading

From the desk.

All insights ->
Strategic guide

In-Licensing China Biotech Assets: Strategic Guide 2026

A practical playbook for Western BD executives on scouting, evaluating, and acquiring Chinese biotech innovation. Due diligence, deal structuring, NMPA data strategy, and BIOSECURE compliance covered.

Regional guide

NMPA Drug Approval Process: Complete Guide 2026

China's FDA equivalent explained. Complete guide to NMPA drug approval pathways, IND filing, Breakthrough Therapy Designation, Conditional Approval, and NDA timelines for global pharma companies.

China brief

Start with a confidential brief from the China desk.

Whether you need a market read, an asset shortlist, an introduction, or a full mandate, share the brief in a line or two. The China desk responds within one business day, NDA-first.

Contact the China desk ->Reply within one business day / NDA-first